By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dako today said that it has signed an agreement with Bristol-Myers Squibb to develop pharmacogenomics tests to identify patients that are more likely to respond to drugs being developed by the drug firm.

The deal builds on a similar agreement between the firms reached in 2008. Terms of the newest agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.